|
|
Clinical Trials
Anne Arundel Medical Center participates
in numerous clinical trials for new cancer treatments. Clinical trials are research studies that have been approved for use. For patients
who have been diagnosed with cancer, participating in a clinical trial
means becoming a part of the fight against cancer. Only through research
can we hope to eradicate the disease. To be able to participate in clinical trials, a hospital must meet certain
guidelines and should have a relatively high volume of patients. AAMC
does both. In addition, the hospital's internal review board approves
the clinical trials.
Contact:
Liz Egan, R.N., Research Nurse
Phone (443) 481-5755
Pager (410) 573-8039
Brain
- RTOG 0424
A Phase III Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low Grade Gliomas
- RTOG: 0420
A Phase II Study of Radiation therapy Plus low dose Temozolomide Followed by Temozolomide Plus Irinotecan for
Glioblasoma Multiforme
- S9811
Phase II Study of Hydroxyurea for Unresectable Meningoma
Breast Cancer
Screening/Diagnosis
- MRI
Use OF MRI in Planning Operative Management of Breast Cancer
- PEM Flex PET Scanner
Prospective Clinical Trial to Establish the Positive Predictive Value of the PEM Flex PET Scanner in
Detecting Additional Cancer Foci Among Women with at Least One Focus of Confirmed Primary Breast
Cancer
Biology
- Komen
Detection of Subclinical Breast Cancer Metastases
- SLND
Accuracy and significance of polymerase chain reaction detection of sentinel node metastases in breast cancer patients.
Adjuvant Therapy
- IBCSG 24-02 - SOFT
A Phase III Trial Evaluating the Role of Ovarian Function Supression and the Role of Exemestane as Adjuvant
Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
- NSABP B-35
A Clinical Trial Comparing Anastrazole with Tamoxifen in Post-Menopausal Patients with
Ductal Carcinoma in Situ (DCIS), undergoing Radiation Therapy with Radiation Therapy
- NSABP B-38
A Phase III, Adjuvant Trial Comparing Three Chemotherapy regimens in Women with Node Positive Breast Cancer:
Docetal/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC-P); DD AC
- NSABP B-39
a Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women
with Stage 0, 1 or II Breast Cancer
- R 9804
Phase III trial of Tamoxifen alone vs Tamoxifen + RT for good risk ductal carcinoma in-situ (DCIS) of the female breast.
Metastatic Disease
- EGF100151
Phase III randomized, Open Label, Multicenter Study Comparing GW572016 and Capecitabine in Women with Refractory
Advanced or Metastatic Breast Cancer
- EGF30008
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole vs.
Letrozole in Subjects with Estrogen / Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer
- XRP9881B-3001
A Randomized Open-Label, Phase III Study of RPR 109881 IV Every 3 weeks vs Capecitabine (Xeloda) Tablets Twice
Daily for 2 weeks in 3-week Cycles in Patients with Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy
Surgery
- CAL vs NWL
Comparative Evaluation of Cryo-Assisted Localization (CAL) vs. Needle Wire Localization (NWL) for Breast Lumpectomy
- NAC
Evaluation of Surgical Impact on Nipple Sensation and Function
Sentinel Lymph Node Biopsy Before Preoperative Chemotherapy; Factors Associated with Non-Sentinel Lymph Node Metastases
Gastrointestinal Cancer
- AVF2941n
An Observational study of Avastin (Bevacizumab) in Combination with Standard Chemotherapy for First-line Treatment of
Metastatic Colorectal Adenocarcinoma
- C80303
A Randomized Phase III Trial of Gemcitabine plus Bevacizumab vs. Gemcitabine plus Placebo in Patients with Advanced
Pancreatic Cancer
- NSABP-C-08
A Phase III Clinical Trial Comparing Infusional 5-FU, Leucovorin and Oxaliplatin Every Two Weeks with Bevacizumab to the
same regimen w/out Bevacizumab for the Treatment of Patients with resected Stage II and III Carcinoma of the Colon V.8/04
- R9811
A Phase III Randomized Study of 5-Fluorouracil, Cisplatin, and Radiotherapy vs. 5
Fluorouracil, Mitomycin-C and Radiotherapy in Carcinoma of the Anal Canal
Genitourinary Cancer (Includes Prostate)
- E3803
Phase III Study of a Weekly Schedule of BMS-247550 for Patients with Hormone Refractory Prostate Cancer
Phase II Chemoprevention Trial of Selenium and Prostate Cancer
- S0000A
Prevention of Alzheimer's Disease with Vitamin E and Selenium (PREADVISE), Phase III Ancillary to S0000
- S0000B
Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE),
Phase II Ancillary to S0000 SELECT
Head and Neck Cancer
- E2303
Phase II Evaluation of Cetuximab (C225) Combined with Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel,
Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck
- E3303
Phase II Study of C225 (Erbitux or Cetuximab) in Combination with Cisplatin and Definitive Radiation in Unresectable Stage IV
Squamous Cell Carcinoma of Head and Neck
- R0129
Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas
Lung Cancer
- CA22S100
A Randomized Multicenter Phase II Study of Gemcitabine / Platinum / Cetuximab vs Gemcitabine / Platinum and First Line
Treatment for Patients with Lung Cancer
- E3598
A Phase III Trial of Carboplatin, Paclitaxel, and Thoracic Radiotherapy, with or without Thalidomide, in Patients with Stage III
NSCLC
- R0212
A Phase II/III Randomized Trial of Two Doses (Phase III - Standard vs High) and Two Dose Schedules (Pahse II - Once vs Twice
Daily) for Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer
- TLK286
Phase III Randomized Study of TLK286 vs. Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small
Cell Lung Cancer
Melanoma
- E1697
Phase III Randomized Study of 4 weeks High Dose Interferon 2b in Stage II B Melanoma
- E 4697
A Randomized, Placebo-controlled Phase III Trial of Yeast Derived GM-CSF vs. Peptide Vaccination vs. GM-CSF Plus Peptide Vaccination vs. Placebo with "No Evidence of Disease" after complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma.
For questions or more information, please contact:
Liz Egan, R.N., Research Nurse
Phone (443) 481-5755
Pager (410) 573-8039
|
24-hour on-call service:
(443) 481-5800
FAX: (443) 481-5808
TDD: (443) 481-1235
How to Get Here
Maps and directions to AAMC and the DeCesaris Cancer Institute
Welcome to the DeCesaris Cancer Institute
Barry R. Meisenberg, M.D. Director Geaton and JoAnn DeCesaris Cancer Institute
The Cancer program at Anne Arundel Medical Center encompasses a large array of programs ranging from prevention, screening, diagnosis, treatment, through survivorship. Many different types of professionals contribute to the care of patients in our programs. It is our goal to provide the best experience possible, no matter where a person encounters the cancer program.
Read the full message by clicking here >>
|
PDF, 30k)
